Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/2a Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zotatifin (Primary) ; Abemaciclib; Fulvestrant; Sotorasib
  • Indications Adenocarcinoma; Advanced breast cancer; B-cell lymphoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Effector Therapeutics

    • Most Recent Events

    • 04 Apr 2024 According to an eFFECTOR Therapeutics media release, company expect to report additional data, including the recommended phase 2 dose (RP2D), in the second half of 2024.
    • 25 Mar 2024 Interim results of mPFS of 7.4 months in the ZFA triplet expansion cohort, published in the eFFECTOR Therapeutics Media Release.
    • 08 Dec 2023 According to an eFFECTOR Therapeutics media release, trial is currently enrolling at 0.28 mg/kg in the ZF doublet evaluating zotatifin combined with fulvestrant and at 0.1 mg/kg in the ZFA triplet. The company expects to report additional data from dose escalation in the first half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top